Enterome, Nestlé Health Science Launch Microbiome Diagnostics Partners to Develop New IBD Treatments

Enterome, Nestlé Health Science Launch Microbiome Diagnostics Partners to Develop New IBD Treatments
France's Enterome and Switzerland's Nestlé Health Science have jointly established Microbiome Diagnostics Partners (MDP), a new company created to discover and develop innovative diagnostics for inflammatory bowel disease (IBD), liver disease and other illnesses. The gut microbiome, or the community of microorganisms that live in human guts, plays a critical role in building up a person’s natural immunity and maintaining good health. The recent progress in metagenomics science — or the study of genetic material directly obtained from environmental samples — has propelled awareness of this underestimated human organ and has made it a health priority of Western medicine. “MDP is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics, nutritional therapies and therapeutics," Greg Behar, CEO of Nestlé Health Science, said in a press release. "Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition and we see also new opportunities being created for personalized nutrition, both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics." Initially, MDP will develop diagnostics to assess and manage IBD, based on Enterome’s IBD110 microbiome-derived mucosal healing biomarker. MDP will also develop diagnostic products for pr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *